WEKO3
アイテム
Carbon Ion Radiotherapy for Pancreatic Cancer
https://repo.qst.go.jp/records/64446
https://repo.qst.go.jp/records/6444658fa3ee7-325d-4d25-b16e-527b25d54cb9
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2011-12-02 | |||||
| タイトル | ||||||
| タイトル | Carbon Ion Radiotherapy for Pancreatic Cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Shinoto, Makoto
× Shinoto, Makoto× Yamada, Shigeru× Yasuda, Shigeo× Imada, Hiroshi× Kamada, Tadashi× Tsujii, Hirohiko× 篠藤 誠× 山田 滋× 安田 茂雄× 今田 浩史× 鎌田 正× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The number of deaths from pancreatic cancer in Japan exceeds 26,000 per year, and the number is increasing every year1. Pancreatic cancer is the fifth leading cause of cancer death and it is considered to be one of the most lethal cancers in Japan. Complete surgical resection is the only curative treatment. However, only a small percentage of patients (10-20%) are candidates for surgical resection because of local progression or metastatic spread at the time of diagnosis2, 3. Even if a curative resection is performed, the disease usually recurs and 5-year survival rates are less than 20% 4, 5. Chemotherapy or chemoradiotherapy is selected as a standard treatment for unresectable pancreatic cancer. However, since pancreatic cancer is often resistant to chemotherapy or radiotherapy, the local control rate is very low. Recently, along with the development of new anticancer agents, the irradiation techniques have greatly progressed following the introduction of highly advanced radiotherapy. However, the outcome from therapy is still not satisfactory, with the median survival being approximately 10 months6, 7. We started phase I/II clinical trial for pre-operative carbon ion radiotherapy (CIRT) with 16 fractions in 4 weeks for resectable pancreatic cancer in 2000 (Figure 1). The purpose of this treatment was to reduce the risk of postoperative local recurrence, which accounts for approximately 50% of total recurrences. We established the tolerance and effectiveness of preoperative CIRT and performed a clinical trial aimed at shortening the fraction size to 8 fractions in 2 weeks beginning in 2003 (Protocol 0203). In addition, we started phase I/II clinical trial for patients with locally advanced pancreatic cancer and showed that the treatment was safe and provided excellent local control rates. Accordingly, we are currently performing a clinical trial of using carbon ion radiotherapy combined with gemcitabine (Protocol 0513). |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 2nd NIRS-ETOILE Joint Symposium on Carbon Ion Therapy | |||||
| 発表年月日 | ||||||
| 日付 | 2011-11-27 | |||||
| 日付タイプ | Issued | |||||
